目的 探讨儿童肉毒中毒的临床特点和神经电生理结果，旨在提高临床医师对该病的认识。 方法 回顾性分析2015年8月—2022年10月湖南省儿童医院神经内科确诊的8例肉毒中毒儿童的临床资料。 结果 8例患儿均有对称性颅神经麻痹和四肢弛缓性麻痹，呈下行性；7例出现呼吸肌麻痹。电生理检查结果显示，复合肌肉动作电位波幅降低5例；高频重复神经电刺激复合肌肉动作电位波幅递增超过40.0% 6例；运动单位动作电位呈短时程、低波幅及多位相4例。 结论 儿童肉毒中毒的主要临床特征为从颅神经开始的对称性、下行性弛缓性麻痹，可出现呼吸肌麻痹；其电生理异常有复合肌肉动作电位波幅降低，高频重复神经电刺激复合肌肉动作电位波幅递增，运动单位动作电位呈短时程、低波幅、多位相。
Abstract
Objective To study the clinical and neuroelectrophysiological features of botulism in children. Methods A retrospective analysis was conducted on the clinical data of eight children who were diagnosed with botulism in the Department of Neurology, Hunan Children's Hospital, from August 2015 to October 2022. Results All eight children were found to have symmetrical cranial nerve palsy and flaccid paralysis of the extremities, with a descending pattern. Seven children presented with respiratory muscle paralysis. Electrophysiological examinations revealed decreased compound muscle action potential (CMAP) amplitudes in 5 children, increased CMAP amplitudes exceeding 40.0% in 6 children during high-frequency repetitive nerve stimulation, and short duration, low amplitude, and polyphasic motor unit action potentials in 4 children. Conclusions The main clinical features of botulism in children include symmetric, descending flaccid paralysis starting from cranial nerves, with the possibility of respiratory muscle paralysis. Electrophysiological abnormalities associated with it include decreased CMAP amplitudes, increased CMAP amplitudes during high-frequency repetitive nerve stimulation, and short duration, low amplitude, and polyphasic motor unit action potentials.
关键词
肉毒中毒 /
临床特征 /
神经电生理 /
儿童
Key words
Botulism /
Clinical feature /
Neuroelectrophysiology /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 邱泽武, 彭晓波. 重视食源性肉毒中毒诊治中的难点和热点问题[J]. 中华急诊医学杂志, 2022, 31(3): 265-269. DOI: 10.3760/cma.j.issn.1671-0282.2022.03.001.
2 田英平, 石汉文, 佟飞, 等. 肉毒中毒诊疗方案[J]. 中华急诊医学杂志, 2010, 19(4): 349-350. DOI: 10.3760/cma.j.issn.1671-0282.2010.04.004.
3 Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities[J]. Disaster Med Public Health Prep, 2007, 1(2): 122-134. PMID: 18388640. DOI: 10.1097/DMP.0b013e318158c5fd.
4 PrestonDC, ShapiroBE. 肌电图与神经肌肉疾病: 从临床到电生理学[M]. 朱冬青, 黎鸣, 朱愈, 译. 3版. 北京: 人民卫生出版社, 2021: 51-59.
5 World Health Organization. Botulism[EB/OL]. (2018-01-10)[2023-01-24]. https://www.who.int/en/news-room/fact-sheets/detail/botulism.
6 Rao AK, Lin NH, Griese SE, et al. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks[J]. Clin Infect Dis, 2017, 66(suppl_1): S38-S42. PMID: 29293926. DOI: 10.1093/cid/cix814.
7 Rao AK, Lin NH, Jackson KA, et al. Clinical characteristics and ancillary test results among patients with botulism: United States, 2002-2015[J]. Clin Infect Dis, 2017, 66(suppl_1): S4-S10. PMID: 29293936. DOI: 10.1093/cid/cix935.
8 Simpson LL. Identification of the major steps in botulinum toxin action[J]. Annu Rev PharmacolToxicol, 2004, 44: 167-193. PMID: 14744243. DOI: 10.1146/annurev.pharmtox.44.101802.121554.
9 Rao AK, Sobel J, Chatham-Stephens K, et al. Clinical guidelines for diagnosis and treatment of botulism, 2021[J]. MMWR Recomm Rep, 2021, 70(2): 1-30. PMID: 33956777. PMCID: PMC8112830. DOI: 10.15585/mmwr.rr7002a1.
10 Azapa?as? E, Kendirli T, ?z-Tuncer G, et al. Complete paralytic botulism mimicking a deep coma in a child[J]. Turk J Pediatr, 2017, 59(5): 581-585. PMID: 29745121. DOI: 10.24953/turkjped.2017.05.012.
11 Raja SM. Lambert-Eaton myasthenic syndrome and botulism[J]. Continuum (MinneapMinn), 2022, 28(6): 1596-1614. PMID: 36537971. DOI: 10.1212/CON.0000000000001205.
12 Boccagni C, Prestandrea C, D'Agostino T, et al. Neurophysiological patterns of acute and post-acute foodborne botulism[J]. Muscle Nerve, 2021, 64(4): 435-444. PMID: 34255868. DOI: 10.1002/mus.27370.
13 Khan MR, Maheshwari PK, Ibrahim SH, et al. Botulism in children: a diagnostic dilemma in developing countries[J]. J Coll Physicians Surg Pak, 2013, 23(6): 443-444. PMID: 23763811.
14 Katirji B, Kaminski HJ. Electrodiagnostic approach to the patient with suspected neuromuscular junction disorder[J]. Neurol Clin, 2002, 20(2): 557-586. PMID: 12152447. DOI: 10.1016/s0733-8619(01)00012-3.
15 Jang HG, Jang J, Jung HJ, et al. The first reported case of infant botulism in Korea: treatable infantile neuromuscular disease[J]. J Korean Med Sci, 2020, 35(14): e93. PMID: 32281313. PMCID: PMC7152530. DOI: 10.3346/jkms.2020.35.e93.
16 Anniballi F, Auricchio B, Fiore A, et al. Botulism in Italy, 1986 to 2015[J]. Euro Surveill, 2017, 22(24): 30550. PMID: 28661393. PMCID: PMC5479972. DOI: 10.2807/1560-7917.ES.2017.22.24.30550.
17 Schussler E, Sobel J, Hsu J, et al. Workgroup report by the joint task force involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup—allergic reactions to botulinum antitoxin: a systematic review[J]. Clin Infect Dis, 2017, 66(suppl_1): S65-S72. PMID: 29293931. PMCID: PMC5850017. DOI: 10.1093/cid/cix827.
18 Yu PA, Lin NH, Mahon BE, et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin[J]. Clin Infect Dis, 2017, 66(suppl_1): S57-S64. PMID: 29293928. PMCID: PMC5866099. DOI: 10.1093/cid/cix816.
19 O'Horo JC, Harper EP, El Rafei A, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923-2016[J]. Clin Infect Dis, 2017, 66(suppl_1): S43-S56. PMID: 29293927. PMCID: PMC5850555. DOI: 10.1093/cid/cix815.
PDF(759 KB)
